About this trial
This study is a pilot, multi-center, observational retrospective-prospective study, with two different Parts, as follows:
1. Part 1(retrospective and prospective part): to evaluate efficacy and safety of switching to BIC/FTC/TAF in People living with HIV (PWH) who previously failed CAB/RPV LAI in the last three years and received in the last three years boosted PI since any INSTI mutations were detected on RNA and/or DNA through NGS at failure 2. Part 2 (prospective part only): to evaluate efficacy and safety of switching directly to BIC/FTC/TAF in PWH who failed CAB/RPV LAI without any RAMs on RNA and/or DNA through NGS considered of potential relevance for bictegravir
Inclusion Criteria:
* PWH with age \>18 years * PWH with a confirmed virological failure on CAB/RPV LAI in the last three years * PWH without RAMs versus FTC and TAF
Study population: 30 subjects failing CAB/RPV LAI will be included in the study
Eligibility criteria
Qualifiers
PWH with age >18 years
PWH with a confirmed virological failure on CAB/RPV LAI in the last three years
PWH without RAMs versus FTC and TAF
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Sponsors and collaborators
Cristina Mussini
Lead sponsor
University of Modena and Reggio Emilia
Sponsor institution